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ABSTRACT
Background and aim Several studies have
highlighted the association of the 12q13.3–12q14.1
region with coeliac disease, type 1 diabetes, rheumatoid
arthritis and multiple sclerosis (MS); however, the causal
variants underlying diseases are still unclear. The authors
sought to identify the functional variant of this region
associated with MS.
Methods Tag-single nucleotide polymorphism (SNP)
analysis of the associated region encoding 15 genes was
performed in 2876 MS patients and 2910 healthy
Caucasian controls together with expression regulation
analyses.
Results rs6581155, which tagged 18 variants within a
region where 9 genes map, was sufﬁcient to model the
association. This SNP was in total linkage disequilibrium
(LD) with other polymorphisms that associated with the
expression levels of FAM119B, AVIL, TSFM, TSPAN31
and CYP27B1 genes in different expression quantitative
trait loci studies. Functional annotations from
Encyclopedia of DNA Elements (ENCODE) showed that
six out of these rs6581155-tagged-SNPs were located in
regions with regulatory potential and only one of them,
rs10877013, exhibited allele-dependent (ratio A/G=9.5-
fold) and orientation-dependent (forward/reverse=2.7-
fold) enhancer activity as determined by luciferase
reporter assays. This enhancer is located in a region
where a long-range chromatin interaction among the
promoters and promoter-enhancer of several genes has
been described, possibly affecting their expression
simultaneously.
Conclusions This study determines a functional variant
which alters the enhancer activity of a regulatory
element in the locus affecting the expression of several
genes and explains the association of the 12q13.3–
12q14.1 region with MS.
INTRODUCTION
Multiple sclerosis (MS) is a chronic autoimmune
disease with a complex pathogenesis in which
demyelination and neurodegeneration are the main
contributors to disability.1 Susceptibility to MS is
thought to be conferred by a combination of genetic
and environmental factors.2 The best characterised
region implicated in predisposition to MS is the
Major Histocompatibility Complex on chromosome
6p21, speciﬁcally the HLA-DRB1* 15:01 class II
allele, but this accounts for less than 50% of MS
heritability.3 New powerful methods as gene expres-
sion proﬁling and genome-wide association study
(GWAS) have provided evidence for new susceptibil-
ity loci implicated in MS.4–6 These comprise over
40 loci including IL2RA, CBLB, IL7R, CLEC16A,
TNFRSF1A, PTGER4 and IRF8.7–9
For many risk loci, the association signals do not
directly implicate a single gene and the causative
role for candidate genes in the region can only be
speculated. A striking number of loci have demon-
strated genome-wide evidence for association in
multiple, distinct autoimmune disorders.10 11 One
of these loci is 12q13–14 which has been asso-
ciated in GWAS for rheumatoid arthritis (RA),
coeliac disease (CD) and MS.8 12–14 However, dif-
ferent genes have been suggested in each study
based on the main associated signal. A
meta-analysis of two published GWAS totalling
3393 RA cases and 12 462 healthy controls identi-
ﬁed an association at rs1678542 localised in the
KIF5A intronic region.13 Another meta-analysis of
two published GWAS on CD (4533 cases and
10 750 controls) and RA (5539 cases and 17 231
controls) described the association of both diseases
at rs10876993 localised in the intergenic region
between B4GALNT1 and OS9 genes.14 Association
at this locus was also described in a MS GWAS per-
formed by the Australian and New Zealand
Multiple Sclerosis Genetics Consortium in 1618
MS-cases. In this case, an associated single nucleo-
tide polymorphism (SNP) (rs703842) was located
at the 3' untranslated region (3' UTR) of the
METTL1 gene.12 The last GWAS performed by
the International Multiple Sclerosis Genetics
Consortium with 10 000 MS patients also reported
the association with this region at rs12368653 in
theAGAP2 gene.8 In candidate gene studies, the
KIF5A variant was demonstrated to be associated to
MS15 and type 1 diabetes.16 Also rare variants
in the CYP27B1 gene have been associated
with MS.17 Other candidate-gene studies had
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demonstrated association of variants located at the CYP27B1
gene with type 1 diabetes18 and MS.19
The FAM119B gene has been pinpointed as the causal gene of
the locus since its expression has been shown to be much lower
in leukocytes of MS patients carrying the MS risk allele.20 On
the other hand, since, in several studies, MS patients have lower
levels of precursors of vitamin D in serum compared with con-
trols, it has been suggested that CYP27B1, an enzyme implicated
in Vitamin D activation, may be the causal gene.19
In this work we performed a ﬁne mapping of the 12q13.3–
12q14.1 region by a Tag-SNP approach to identify the poly-
morphism leading the association with MS. We also performed
functional studies to determine the involvement of the asso-
ciated MS risk variants in gene expression.
MATERIAL AND METHODS
Study subjects and SNP genotyping
The entire data set studied consisted of 2876 MS patients diag-
nosed following Poser’s criteria21 and 2910 age and gender
matched healthy controls, mostly blood donors and staff,
matched by age, gender, ethnicity and place of recruitment.
Patients and control subjects were included in the study based
upon written informed consent. Demographic and clinical char-
acteristics of the sample collections have been published
before15 22 (a summary is in the online supplementary table S1).
SNPs were genotyped using the iPLEX Sequenom MassARRAY
platform in the Spanish National Genotyping Center’s facilities
at Santiago de Compostela University (http://www.cegen.org).
All DNAs ware received in the Centro Nacional de Genotipado
(CEGEN) centre for genotyping in 96-well plates; the concen-
tration of double-stranded DNA was assessed using PicoGreen
(Molecular Probes). As quality control, two trios of Center for
the Study of Human Polymorphisms (CEPH) samples were gen-
otyped (CEPH Na10830, Na10831, Na12147, Na10860,
Na10861, Na11984). The genotypes of these samples corre-
sponded with the ones deposited in HapMap with no detection
of Mendelian inconsistencies. Additionally, a 10% of random
samples were subjected to regenotyping. The resulting data were
concordant with an average accuracy over 99.9%. We per-
formed quality ﬁltering of both samples and SNPs to ensure
robust association testing.
Ethics statement
All participants provided a written informed consent to partici-
pate in this study, which was approved by the Institutional
Review Board of Hospital Regional Universitario Carlos Haya
of Malaga, Hospital Clinic of Barcelona, Hospital Virgen
Macarena of Sevilla, Hospital de Basurto of Bilbao, Hospital
Clínico San Carlos of Madrid, Hospital Universitari Vall d´
Hebron of Barcelona and Hospital Donostia of San Sebastian.
Luciferase assays
Six fragments in both orientations with potential regulatory
activity, as indicated by ENCODE, containing the tagged var-
iants, 24 inserts in total, plus a plasmid without insert, were
assayed for luciferase activity. Thus, fragments I–VI were PCR
ampliﬁed (the coordinates and the primer used are indicated in
online supplementary table S2) using DNA from homozygous
individual for each allele of rs6581155. The fragments were pre-
viously cloned in Vaccinia DNA Topoisomerase I (TOPO) T/A
vector (Invitrogen) and sequenced. Then, each clone was intro-
duced in forward and reverse orientation in pGL4.25 (luc2CP/
minP) vector which contains a minimal promoter upstream of
the luciferase reporter gene luc2CP. Triplicates were transfected
into human Raji cells (ATCC CCL86). The Raji cell line was
maintained in Roswell Park Memorial Institute (RPMI) 1640
medium, supplemented with 10% fetal calf serum, 2.0 mM glu-
tamine, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES), 1 mM streptomycin, 100 U/ml penicillin,
0.05 mM 2-mercaptoethanol. Exponentially growing cells were
transfected by nucleofection Amaxa Cell Line Nucleofector Kit
V (Lonza) according to manufacture protocols. Brieﬂy, Raji cells
(2×106) were mixed with I–VI plasmid constructs or pGL4.25
control plasmid 2 μg of DNA and 0.2 μg of DNA of Renilla luci-
ferase reporter gene plasmid pRL-TK(Promega) for normalising
transfection efﬁciency. The transfected cells were cultured in 12
well-plates for 24 h. Cells were harvested and washed twice in
Phosphate Buffered Saline (PBS) at 4°C. Luciferase activity was
evaluated using Dual-Luciferase Assay System (Promega) accord-
ing to manufacturers. For analysis, lysates were thawed on ice
and the protein concentration was measured by the Bradford
method. Then, 40 μg of protein from all supernatants were ana-
lysed for both ﬁreﬂy and Renilla luciferase activities in a lumin-
ometer F12 (Berthold Detection Systems). The following
equation was used to determine the normalised fold changes in
activity between tested groups:
FoldActivity ¼ ðFirefly=RenillaÞfromconstruct=
ðFirefly=RenillaÞfromemptyplasmid
The normalised fold changes in activity from each of the
three experiments are then averaged together.
Statistical analysis
Departure from Hardy-Weinberg equilibrium for all the biallelic
SNP markers was tested using an exact test.23 Raw data were
analysed for comparison of allele and genotype counts using
PLINK V.1.05. To avoid false-positive results due to multiple
testing and considering that the SNPs analysed are not in com-
plete disequilibrium, we applied the Benjamini-Hochberg
method24 that is robust against positive dependence and con-
trols the false discovery rate.25 In order to determine the effect
and independence of variant association with MS, multiple
logistic regression models were computed. Linkage disequilib-
rium (LD) patterns between SNPs were analysed with
Haploview 4.2.26 Gender was analysed for potential differential
risk contribution. We used the Breslow-Day Test to evaluate the
homogeneity between gender cohorts. The age of onset with
respect to the genotypes was analysed by the Kruskal-Wallis test.
RESULTS
A tag-SNP association study of the region
We performed the ﬁne mapping of the 12q13.3–12q14.1 region
between coordinates 56227468 to 56469005 (B36) (ﬁgure 1).
To analyse this region, 16 SNPs were chosen by pairwise tagging
from the HapMap B36 Utah residents with Northern and
Western European ancestry from the CEPH collection (CEU)
population which captured 89 markers with r2≥0.8 (mean
r2=0.93) and a minor-allele frequency ≥0.1. These tag-SNPs
captured the variants associated with RA, MS and CD previ-
ously reported in different GWAS (see online supplementary
table S3).
Tag-SNPs were genotyped in 2895 MS patients and 2942
healthy controls, mostly blood donors, matched by age, gender,
ethnicity and place of recruitment. The genotypic distribution
between cases and controls is shown in table 1. The genotype fre-
quencies were ﬁtted to an additive model. The top associated
SNP was rs6581155 (p=4.57E−7; OR=0.79; 95% CI 0.73 to
0.87). We performed a logistic regression analysis to determine
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the effect of further independent variants, by testing the addition
of each SNP to rs6581155 and by adding this polymorphism to
each one of the other Tag-SNPs (table 2). The results showed
that, in addition to generate the strongest signal, rs6581155
alone was sufﬁcient to model the association in the locus.
Stratiﬁcation by gender and age at onset and genotypes of
rs6581155 SNP showed absence of statistical signiﬁcance.
Moreover, we genotyped the rare variant rs118204009
located in the CYP27B gene that has been recently associated
with MS in a subgroup of 1006 patients and 1044 healthy
Figure 1 Scheme of the 12q13.3–12q14.1 region. The illustration shows from top to bottom the following parts as indicated : Scale and
chromosomal position (B36/gh18); (in blue) diseases-associated variants as reported in different genome-wide association study (RA, rheumatoid
arthritis; CD, coeliac disease; MS, multiple sclerosis); Tag-SNPs analysed in the present work; (in red) MS-associated rs6581155-tagged variants with
r2≥0.8 and a minor-allele frequency <0.1; Ref-Seq genes present in the region; the LD structure represented by r-square for the CEU population.
Table 1 Association study of the different Tag-SNPs with multiple sclerosis
SNP
Alleles Multiple sclerosis Healthy controls Allelic p value
1 2 11 12 22 11 12 22 Uncorrected
Benjamini-Hochberg
Adjusted
Per allele OR
(95% CI)
rs1678542 C G 248 (9) 1149 (41.7) 1361 (49.3) 318 (11.2) 1229 (43.3) 1291 (45.5) 0.0005 0.0017 0.87 (0.8 to 0.94)
rs2888334 C G 134 (4.7) 946 (33.2) 1770 (62.1) 166 (5.7) 1030 (36.9) 1676 (58.4) 0.002 0.004 0.87 (0.8 to 0.95)
rs775249 T C 181 (6.4) 1047 (36.8) 1619 (56.9) 181 (6.3) 1100 (38.2) 1601 (55.5) 0.44 0.51 0.97 (0.89 to 1.05)
rs1678536 G C 129 (4.5) 922 (32.4) 1796 (63.1) 163 (5.7) 1013 (35.2) 1701 (59.1) 0.001 0.0023 0.86 (0.79 to 0.94)
rs7313599 G A 752 (26.4) 1399 (49.1) 696 (24.5) 660 (23) 1430 (49.7) 784 (27.3) 0.0008 0.0021 1.13 (1.05 to 1.22)
rs1078109 A G 6 (0.2) 366 (12.9) 2472 (86.9) 8 (0.28) 306 (10.6) 2568 (89.1) 0.018 0.026 1.2 (1.03 to 1.4)
rs7305391 A G 128 (4.5) 908 (31.9) 1813 (63.6) 119 (4.1) 967 (33.6) 1792 (62.3) 0.5 0.537 0.97 (0.89 to 1.06)
rs1564374 G A 477 (17.2) 1383 (49.9) 909 (32.8) 570 (20.9) 1349 (49.4) 812 (29.7) 0.00037 0.0015 0.87 (0.81 to 0.94)
rs11172290 G A 58 (2) 735 (25.8) 2052 (72.1) 73 (2.5) 726 (25.2) 2082 (72.2) 0.79 0.79 0.99 (0.89 to 1.09)
rs3825078 A T 176 (6.2) 1115 (39.1) 1558 (54.7) 238 (8.2) 1149 (40) 1497 (51.9) 0.003 0.006 0.88 (0.81 to 0.96)
rs701006 A G 222 (7.8) 1225 (43) 1403 (49.2) 318 (11) 1266 (44) 1295 (45) 0.000014 0.00008 0.84 (0.78 to 0.91)
rs2301551 G C 76 (2.7) 867 (30.5) 1897 (66.8) 130 (4.5) 967 (33.7) 1769 (61.7) 3.22E−6 0.00003 0.8 (0.73 to 0.88)
rs12307841 C T 26 (0.9) 518 (18.1) 2311 (80.9) 28 (0.97) 469 (16.3) 2386 (82.7) 0.1097 0.15 1.11 (0.98 to 1.25)
rs12368653 G A 430 (15.1) 1403 (49.2) 1016 (35.7) 502 (17.5) 1413 (49.2) 955 (33.3) 0.009 0.015 0.91 (0.84 to 0.98)
rs1048691 T C 135 (4.8) 958 (33.8) 1738 (61.4) 127 (4.4) 940 (32.7) 1805 (62.8) 0.24 0.29 1.06 (0.96 to 1.15)
rs6581155 G A 110 (4) 909 (32.7) 1757 (63.3) 173 (6.2) 1002 (36.2) 1596 (57.6) 4.57E−7 7.3E−6 0.79 (0.73 to 0.87)
Counts (percentages in brackets) are represented for each genotype.
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controls.17 We did not detect this polymorphism in any individ-
ual of the MS or control groups (data not shown).
Association of rs6581155-tagged SNPs with gene
transcription levels
To determine if selected Tag-SNPs could have a functional effect
on the transcription levels of the genes located in the 12q13.3–
12q141 region, we ﬁrst used expression quantitative trait loci
(eQTL) data from Zeller et al27 obtained from monocyte
samples of 1490 German individuals (http://genecanvas.ecgene.
net/news.php?readmore=45). There were 23 eQTLs for
FAM119B, 6 for AVIL, 18 for XRCC6BP1, 18 for TSFM and 20
for TSPAN31 genes in the whole region. The variants best corre-
lated with expression of FAM119B, AVIL, TSFM and
TSPAN31were also SNPs tagged by rs6581155 and, therefore,
in high LD with it (r2>0.8) (table 3). The eQTLs for the
XRCC6BP gene were in low LD with rs6581155 (r2=0.18) indi-
cating that they were not involved in MS risk. Interestingly, the
minor alleles for the rs6581155-tagged SNPs, which were pro-
tective for MS, correlated with high expression of FAM119B
and AVIL but low expression of TSFM and TSPAN31 (see online
supplementary ﬁgure S1) although there were large differences
between the correlation coefﬁcients obtained for each gene.
FAM119B was the gene most strongly correlated with the
rs6581155-tagged SNPs in monocytes.
The eQTL data from Dixon et al28 obtained in lymphoblastic
cell lines (LCL) from 206 families of British descent conﬁrmed
the eQTLs previously observed for FAM119B and TSFM,
although the correlation coefﬁcients were similar for both genes
in contrast to the data from Zeller et al.27 The eQTLs for
FAM119B were also reported in three additional data sets
carried out in different cell types, as shown in table 3.
The data from Montgomery et al,29 obtained by RNA-Seq
from LCL of 60 HapMap CEU individuals, have reported a
rs6581155-tagged SNP to be eQTLs for FAM119B and
CYP27B1, in which the minor allele inversely correlated with
high expression of these genes (correlation coefﬁcient (r) for
CYP27B1=−0.472, and for FAM119B=−0.474).
Enhancer activity
Since all the rs6581155-tagged polymorphisms were located in
intronic and intergenic non-coding regions, another strategy
to search for functionality was to use annotations of gene regula-
tory regions from ENCODE (http://genome.ucsc.edu/cgi-bin/
hgTrackUi?hgsid=173506627&c=chr8&g=wgEncodeReg). Six
out of 18 captured SNPs were located in remarkable regions asso-
ciated with histone methylation, binding sites of transcription
factors or in DNAse I hypersensitive site as shown in ﬁgure 2A.
To test their potential activities as enhancers or repressors of
gene expression, we cloned the fragments containing these six
variants upstream of the basic promoter of a luciferase reporter
system and transfected into Raji lymphoblastic B cells.
We cloned four inserts for each of the six regions carrying
both alleles in forward and reverse orientation. Only region III
containing variant SNP rs10877013 had allele-dependent and
orientation-dependent enhancer activity. Thus, allele A versus
allele G in forward orientation showed 9.5-fold higher ratio of
luciferase activity (ﬁgure 2B). We observed a 2.7 times higher
enhancer activity of the T allele in the reverse fragment.
TFSEARCH, Match and TESS software were used to predict
potential transcription factor binding sites that could be respon-
sible of the different allele-depending activity of fragment III.
The SNP rs10877013 falls within the putative binding sites for
the CCAAT/enhancer binding proteins (C/EBP) α and β.
Although both alleles appear to be consistent with the consensus
sequence for C/EBP TF it is possible that a base change could
affect the afﬁnity or isotype binding of the C/EBP transcription
factor to the sequence.
DISCUSSION
The 12q13.3–12q14.1 region has been associated to several
autoimmune diseases8 12–16 but no causal variant has been
found so far for any of them exception made for a rare variant
Table 2 Regression analyses of the 16 Tag SNPs
SNP A1
*Add locus to rs6581155 †Add rs6581155 to locus
p OR (95% CI) p OR (95% CI)
rs1678542 C 0.2223 0.94 (0.86 to 1.04) 0.0001393 0.82 (0.74 to 0.91)
rs2888334 C 0.8487 0.99 (0.89 to 1.1) 0.0001001 0.8 (0.72 to 0.9)
rs775249 T 0.1719 0.94 (0.86 to 1.03) 3.99E−07 0.79 (0.72 to 0.87)
rs1678536 G 0.7964 0.99 (0.88 to 1.1) 9.86E−05 0.8 (0.72 to 0.9)
rs7313599 G 0.1479 1.06 (0.98 to 1.15) 6.20E−05 0.82 (0.74 to 0.9)
rs1078109 A 0.09391 1.15 (0.98 to 1.35) 1.42E−06 0.8 (0.73 to 0.88)
rs7305391 A 0.2615 0.95 (0.87 to 1.04) 6.29E−07 0.8 (0.73 to 0.87)
rs1564374 G 0.2487 0.95 (0.86 to 1.04) 0.000759 0.83 (0.74 to 0.93)
rs11172290 G 0.634 0.98 (0.88 to 1.08) 4.10E−07 0.79 (0.73 to 0.87)
rs3825078 A 0.589 1.03 (0.93 to 1.14) 1.36E−05 0.78 (0.7 to 0.87)
rs701006 A 0.4727 0.96 (0.85 to 1.08) 0.003056 0.82 (0.72 to 0.94)
rs2301551 G 0.1587 0.88 (0.75 to 1.05) 0.1069 0.88 (0.75 to 1.03)
rs12307841 C 0.6206 1.03 (0.91 to 1.17) 1.23E−06 0.8 (0.73 to 0.87)
rs12368653 G 0.5573 1.03 (0.93 to 1.14) 1.74E−05 0.78 (0.69 to 0.87)
rs1048691 T 0.795 1.01 (0.92 to 1.11) 1.80E−06 0.8 (0.72 to 0.87)
rs6581155 G NA NA NA NA
Results for models assuming additive effects.
*Denotes results adjusted for rs6581155.
†Denotes results adjusted for locus tested.
NA, not applicable.
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Table 3 rs6581155 tagged SNPs that have been reported to be eQTLs in the region
Study Zeller et al27 Dixon et al28 Montgomery et al29 Stranger et al30 Dimas et al31
Population 1490 German individuals 206 families of British descent
60 CEU individuals of the HapMap
collection 60 individuals of the
HapMap collection CEU
80 individuals of Western European origin
Gene AVIL XRCC6BP1 TSFM FAM119B TSPAN31 FAM119B TSFM CYP27B1 FAM119B FAM119B FAM119B FAM119B FAM119B
Cell type Monocytes LCL LCL LCL T-cells LCL Fibroblasts
Probe/Transcript ILMN_20148 ILMN_16915 ILMN_27946 ILMN_12426 ILMN_11441 213861_s_at 212656_at ENST00000228606 ENST00000300209 GI_24308058-S ILMN_1723846 ILMN_1723846 ILMN_1723846
p Value/effect p Value/effect p Value/effect p Value/effect p Value
SNP
rs6581155 2.1E−10/−0.57
rs10747783 5.00E−21/−0.731 9.00E−13/0.564 7.5E−11/−0.58
rs923829 5.00E−21/−0.731 9.00E−13/0.564 6E−11/−0.58
rs10431552 2.80E−21/−0.745 1.00E−12/0.569 2.1E−10/−0.57
rs2072052 7.70E−19/−689 1.00E−13/0.588 5E−10/−0.56
rs2291617 4.10E−11/−0.62 7.60E−11/0.626 6E−11/−0.58
rs4646536 1.7E−07/−0.021 5E−38/0.11 7.71E−19/0.055 3.34E−236/−0.52 1.4E−11/0.033 2.1E−10/−0.57
rs724834 6E−11/−0.58
rs2069502 1.84E−08/−0.024 4.4E−38/0.11 6.19E−17/0.049 7.78E−221/−0.5 2.29E−12/0.036 7.7E−19/−0.689 1.40E−13/0.583 5.3E−10/−0.56
rs10877013 8.80E−20/−0.711 1.80E−12/0.56 4.1E−10/−0.56 0.000012/−0.481 0.000292/−0.407 0.0000001/−0.571
rs10877011 8.90E−14/−0.612 9.00E−13/0.6 0.00014157/−0.472 0.00013264/−0.474 9.5E−11/−0.57
rs701008 2.30E−12/−0.563 2.30E−11/0.55 1.6E−8/−0.51
rs8181644 1.2E−07/−0.022 3.8E−38/0.11 1.4E−19/0.057 3.9E−234/−0.52 5.5E−12/0.034 2.1E−10/−0.57
rs10877019 4.2E−07/−0.023 6.31E−38/0.11 1.024E−190.058 8.32E−233/−0.52 1.52E−11/0.034 2.1E−10/−0.57
rs11172335 2.1E−10/−0.57
rs703842 1.67E−07/−0.021 2.42E−37/0.11 1.42E−18/0.054 7.5E−235/−0.52 1.41E−11/0.037 7.80E−17/−0.694 2.50E−11/0.568 2.1E−10/−0.57
rs10877015 2.1E−10/−0.57
rs11172333 1.11E−07/−0.023 7.31E−39/0.11 1.74E−19/0.057 2.07E−233/−0.51 5.63E−12/0.035 2.1E−10/−0.57
Zeller et al Genome-Wide Expression analysis performed with Illumina HT-12 v3 BeadChip. Association significance was obtained by ANalysis Of VAriance (ANOVA).
Dixon et al Genome-Wide Expression analysis performed by U133 Plus 2.0 GeneChips (Affymetrix). Association analysis was obtained by fitting a simple regression model to each trait and used a variance component approach to account for correlation
between different observed phenotypes within each family.
Montgomery et al Genome-Wide Expression analysis performed by RNA sequencing in an Illumina GAII. Association analysis and multiple testing corrections were conducted by spearman rank correlation and permuting the expression phenotype 10 000
times and summarising the extreme p value distribution for each particular exon, transcript and probe.
Stranger et al Genome-Wide Expression analysis performed with Sentrix Human-6 Expression BeadChip V.1, Illumina. Association significance was obtained by spearman rank correlation with 10 000 permutations of the expression phenotypes.
Dimas et al Gene expression was performed by commercial whole-genome expression array (WG-6 V.3 Expression BeadChip, Illumina). Association analysis and multiple testing corrections were conducted by spearman rank correlation. Thresholds for each
gene were assigned after 10 000 permutations of expression values relative to genotypes where the haplotypic (LD) structure was maintained in each interaction.
eQTL, expression quantitative trait loci; LCL, lymphoblastic cell lines.
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in the coding region of CYP27B1 gene associated with MS.17
This variant was not detected in our sample set.
In the present work, by integrating several strategies, we have
uncovered the variant most strongly associated with MS in the
region. This variant also affects the activity of an enhancer in an
allele-dependent and orientation-dependent manner and corre-
lates with the expression of ﬁve genes of the locus. Interestingly,
the major allele of this SNP (rs10877013) correlates with high
luciferase activity and at the same time with high expression of
TSFM and TSPAN31 and low expression of FAM119B,
CYP27B1 and AVIL. Although it could seem contradictory that
one enhancer may differentially affect the expression of differ-
ent genes, parallel situations have been described extensively in
two scenarios: ﬁrst, the same transcription factor is capable of
activating or repressing depending on the context;32 33 second,
a single DNA sequence can be bound by different factors with
opposite activities.34 On the other hand, we cannot forget the
important role of H3K4me preventing aberrant gene expression
or modulating transcriptional response. H3K4me turns to mark
for both positive and negative regulation. The role of H3K4me2
in histones deacetylation could serve as a ﬁne-tuning regulatory
mechanism.35
It has been described that interacting promotes are coex-
pressed in a tissue-speciﬁc manner. Based on the Chromatin
Interaction Analysis with Paired-End-Tag sequencing results
mapping long-range chromatin interactions associated with
RNAPII and H3K4me2,36 37 we observed that the genes in the
analysed region are engaged through promoter–promoter, pro-
moter–enhancer interactions forming a multigene complex
that could provide a structural framework for cotranscription
(ﬁgure 3). In this sense, the effect of a polymorphism on one
enhancer embedded in this multigene complex could have diver-
ging effects depending on the interaction of this enhancer with
the different promoters. Additionally, the interactions could be
tissue-type or cell-type speciﬁc, as has been shown by Li et al.36
Therefore, it is not evident which of the genes in the region
may be responsible for the genetic association with MS, since
they seem to be coordinately regulated, and the enhancer con-
taining the MS-associated variant may be affecting either of
them; in fact, it acts as an eQTL for all of them. We observed
that the Spearman’s correlation coefﬁcients (r) between the
expression levels of the different genes in this cluster and the
rs6581155-tagged SNPs were different in the different assays
performed. For instance, in monocytes the best correlation is
observed with FAM119B (r=−0.52), however in data obtained
from LCL by RNA-seq a medium-high correlation coefﬁcient
is found for both CYP27B1 (r=−0.472) and FAM119B
(r=−0.474), and with microarrays the correlation coefﬁcient is
Figure 2 Enhancer-suppressor activity of the rs6581155-tagged variants. (A) Schematic illustration to show the localisation of the six tagged SNPs
(in red) in potential regulatory regions (in black, I–VI) as indicated by ENCODE for the GM12878 lymphoblastoid cell line and the genes present in
the region: Enhancer H3K4Me1 track shows where modiﬁcation of histone proteins is suggestive of enhancer; Promoter H3K4Me3 track shows a
histone mark associated with promoters; Layered H3K4Me3 track shows histone mark associated with promoters that are active or poised to be
activated; DNase Clusters track shows regions where chromatin is hypersensitive to DNase I enzyme; Txn Factor ChIP track shows DNA regions
where transcription factors bind to DNA as assayed by chromatin immunoprecipitation (ChIP) with antibodies speciﬁc to the transcription factor
followed by sequencing of the precipitated DNA (ChIP-Seq). (B) Δ Fold luciferase activity respect to the empty vector of the different constructs
corresponding to the six regions (I–VI) with potential regulatory activity, containing the rs6581155 tagged polymorphisms transfected into Raji B
cells. Four clones for each region bearing the different alleles (allele m, minor and M, major) and in both orientations (Forward and Reverse) from
three independent transfection experiments are represented. Luciferase activity levels are referred to the level of the control plasmid containing only
the basic promoter and the Renilla activity.
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very similar for TSFM and FAM119B. Based on data from LCL
cells, TSFM, FAM119B or CYP27B1 would be candidates, while
FAM119B appears to emerge from monocytes. In fact, Gandhi
et al20 reported that FAM119B expression level was much lower
in MS patients carrying the susceptibility haplotype. We
observed that this correlation occurs also in samples from
healthy donors as they are the CEU HapMap samples.
However, we do not know the precise conditions (cell type,
stage of disease, etc) under which expression of these genes
could be determinant for the development of MS. For the same
reason the variant-speciﬁc enhancer activity of fragment III,
reported in this work, could vary in different cell-types. Here
we have used in the activity assays the same cell-type used in the
eQTL analysis to reproduce the effect observed in the expres-
sion of these genes. The Raji cells are lymphoblast-like cells
derived from B-lymphocyte as the LCL from HapMap. The
effect of the enhancer on the gene expression of proximal
tubule cells of the kidney and the disease-activated macro-
phages, which are the major source of CYP27B1,38 could shed
light on the involvement of this variant in MS.
Relying on published data from other groups on the concen-
tration of precursors of vitamin D in serum, two independent
groups reported a correlation between the major alleles of
rs703842, tagged by rs6581155 in the present work, with high
25-hydroxyvitamin D (25(OH)D) concentrations in MS
patients.39 40 On the other hand, Lange et al41 reported a cor-
relation of the major allele of rs10877012, in total LD with
rs6581155, and low 1,25(OH)2D serum levels. The major allele
of the MS-associated SNPs, in total LD with the previously
mentioned SNPs, correlated with low expression of the
CYP27B1 gene. This enzyme catalyses the conversion of 25
(OH)D to 1,25(OH)2D, thus a low expression of this enzyme,
could reconcile the above seemingly conﬂicting data, via accu-
mulation of 25(OH)D and a low 1,25(OH)2D product. These
data support the CYP27B1 gene as a very plausible candidate
gene for association of the region with MS.
Vitamin D, besides having well-known control functions of
calcium and phosphorus metabolism, bone formation and min-
eralisation, also has a complex role in the maintenance of
immune homeostasis. The administration of vitamin D in
animal models leads to improvement of immune-mediated
symptoms. The correlation between the MS- associated variants
and circulating levels of vitamin D supports the important role
of vitamin D in susceptibility to MS. Thus, if this is the case in
human MS, both the pharmacogenomics and the expression
analysis of all the genes affecting the causing factor can reveal
the kind of intervention necessary for neutralising a pathogenic
situation.42
In this work we localise a group of variants in almost total
LD that explain the association of the 12q13.3–12q14.1 region
with MS. One of these variants (rs10877013) strongly affects
the activity of one enhancer in the region, in an allele-
dependent and orientation-dependent way, that could be the
cause of the alteration of TSFM, TSPAN31, FAM119B,
Figure 3 Datasets on Long-Range Chromatin Interaction with Paired-End-Tag sequencing (ChIA-PET) in the studied region. (A) Coordinates of
chr12 in B37 and known genes by University of California Santa Cruz (UCSC) browser. (B) H3K4me2 ChIA-PET data obtained from CD4 T cells, data
from Chepelev et al.37 (C) RNAPII ChIA-PET data obtained in K562 cells (data from Li et al36) In red, the number of the PET-counts (PETc) of the
most frequent interactions is indicated. (D) RNAPII ChIA-PET data obtained in MCF7 cells.36 The most frequent interactions are indicated in red. (E)
ENCODE information on transcription levels assayed by sequencing of polyadenylated RNA from K562 cells. (F) ENCODE information on the RNAPII
binding sites by ChIP-seq. (G) H3K4Me3 histone mark in K562 cells associated with promoters. (H) H3K4Me1 modiﬁcation of histone proteins in
K562 cells, suggestive of enhancer and, to a lesser extent, other regulatory activity.
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CYP27B1 and AVIL gene expression, due to the promoter multi-
gene interactions observed in the region. Some of the tagged
variants have been described to be associated with the vitamin
D serum concentration. Our results point to one of these as the
causal gene for MS association in the locus.
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